9 days ago
The Dallas Cowboys came into Lambeau Field on Sunday Night Football with a high-powered offense. Dak Prescott and company led the offense in many drive-based statistics, including the percentage of offensive drives ending in a score, plays per drive, and yards per drive.
Against Jonathan Gannon's aggressive Green Bay Packers defense, the Cowboys managed just seven points on nine offensive drives as the green and gold expanded their league-leading interception numbers. Evan Williams and rookie Brandon Cisse each picked off Dak Prescott, who was under pressure all night long, as the defense led the way in a 23-13 win that improved the Packers' record to 4-2.
Prescott's counterpart, Jordan Love, shook off an early interception of his own to put up a high-quality performance. That pick could have been a truly game-changing play, as it was originally returned for a touchdown that would have tied the game at 7 early on. Instead, the scoring return was nullified on review and the Packers' defense ended up getting a stop to keep Dallas off the scoreboard. The Packers' offense went on to convert each of their first seven third-down opportunities and finished 11-of-18 for the game as Love delivered under pressure time and time again.
Ultimately, Love failed to record multiple touchdown passes for the first time in a game all season, but it wasn't for lack of trying; he saw three potential touchdown passes get dropped by his receivers, but still managed to throw for 276 yards. Matthew Golden was the biggest offender, with two of those dropped scores and a third drop later in the game, but he did end the game with an excellent stat line: six catches for 104 yards and the only receiving touchdown of the game. Additionally, Love did end up being responsible for a second touchdown, getting the Packers' other score on a quarterback sneak just before halftime as the team led 17-0 heading into the break.
The Green Bay defense kept up its excellent play in the second half. After giving up a single touchdown early in the third quarter, they forced turnovers on downs twice in the fourth before allowing a touchdown in garbage time while holding a 16-point lead — though they came up with a big stop on the two-point conversion to largely put an end to the game.
#love
Against Jonathan Gannon's aggressive Green Bay Packers defense, the Cowboys managed just seven points on nine offensive drives as the green and gold expanded their league-leading interception numbers. Evan Williams and rookie Brandon Cisse each picked off Dak Prescott, who was under pressure all night long, as the defense led the way in a 23-13 win that improved the Packers' record to 4-2.
Prescott's counterpart, Jordan Love, shook off an early interception of his own to put up a high-quality performance. That pick could have been a truly game-changing play, as it was originally returned for a touchdown that would have tied the game at 7 early on. Instead, the scoring return was nullified on review and the Packers' defense ended up getting a stop to keep Dallas off the scoreboard. The Packers' offense went on to convert each of their first seven third-down opportunities and finished 11-of-18 for the game as Love delivered under pressure time and time again.
Ultimately, Love failed to record multiple touchdown passes for the first time in a game all season, but it wasn't for lack of trying; he saw three potential touchdown passes get dropped by his receivers, but still managed to throw for 276 yards. Matthew Golden was the biggest offender, with two of those dropped scores and a third drop later in the game, but he did end the game with an excellent stat line: six catches for 104 yards and the only receiving touchdown of the game. Additionally, Love did end up being responsible for a second touchdown, getting the Packers' other score on a quarterback sneak just before halftime as the team led 17-0 heading into the break.
The Green Bay defense kept up its excellent play in the second half. After giving up a single touchdown early in the third quarter, they forced turnovers on downs twice in the fourth before allowing a touchdown in garbage time while holding a 16-point lead — though they came up with a big stop on the two-point conversion to largely put an end to the game.
#love
20 days ago
The "American Dream" costs about $5.3 million over a lifetime, up 4.1% from last year's updated total and faster than wages grew.
The costs of owning a house, paying for new cars and retirement expenses make up nearly 70% of the overall total.
Healthcare and car ownership prices were little changed from last year, but up substantially from five years ago.
The cost of the American Dream is rising faster than our paychecks can cover it.
That's according to an Investopedia ***** ysis of eight classic milestones: owning a home, buying new cars, raising two children and sending them to college, retiring, paying for healthcare, having a wedding, owning pets, and taking a yearly vacation. The lifetime tab, $5.3 million, is up 4.1% from a year ago. By comparison, private-sector wages and salaries in the 12 months through June rose 3.1%, according to the Bureau of Labor Statistics' Employment Cost Index.
#dream #last #total
The costs of owning a house, paying for new cars and retirement expenses make up nearly 70% of the overall total.
Healthcare and car ownership prices were little changed from last year, but up substantially from five years ago.
The cost of the American Dream is rising faster than our paychecks can cover it.
That's according to an Investopedia ***** ysis of eight classic milestones: owning a home, buying new cars, raising two children and sending them to college, retiring, paying for healthcare, having a wedding, owning pets, and taking a yearly vacation. The lifetime tab, $5.3 million, is up 4.1% from a year ago. By comparison, private-sector wages and salaries in the 12 months through June rose 3.1%, according to the Bureau of Labor Statistics' Employment Cost Index.
#dream #last #total
21 days ago
From a purely statistical standpoint, Wall Street has thrived under President Donald Trump. During his first, non-consecutive term, the timeless Dow Jones Industrial Average (DJINDICES:^DJI), benchmark S&P 500 (SNPINDEX:^GSPC), and tech-focused Nasdaq Composite (NASDAQINDEX:^IXIC) gained 57%, 70%, and 142%, respectively. We've witnessed something of an encore performance since the beginning of his second term in January 2025.
The Trump bull market is being fueled by the artificial intelligence (AI) infrastructure build-out, much better-than-expected corporate earnings, and record share buybacks. The president's first-term tax-and-spending law, the Tax Cuts and Jobs Act (signed into law December 2017), spurred the latter by reducing the peak marginal corporate income tax rate to 21%, the lowest level since 1939.
Missed AI's "Act 1"? Act 2 Could Be 14x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our ***** ysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
Image source: Official White House Photo by Daniel Torok.
But things may not be as perfect for the stock market as the Dow's, S&P 500's, and Nasdaq Composite's gains imply. An ominous $8.44 trillion figure with historical precedent at its back looms large, implying that the Trump bull market is operating on borrowed time.
#term
The Trump bull market is being fueled by the artificial intelligence (AI) infrastructure build-out, much better-than-expected corporate earnings, and record share buybacks. The president's first-term tax-and-spending law, the Tax Cuts and Jobs Act (signed into law December 2017), spurred the latter by reducing the peak marginal corporate income tax rate to 21%, the lowest level since 1939.
Missed AI's "Act 1"? Act 2 Could Be 14x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our ***** ysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
Image source: Official White House Photo by Daniel Torok.
But things may not be as perfect for the stock market as the Dow's, S&P 500's, and Nasdaq Composite's gains imply. An ominous $8.44 trillion figure with historical precedent at its back looms large, implying that the Trump bull market is operating on borrowed time.
#term
1 month ago
Millions of Americans recently received unwelcome news about their cell phone bills.
In late June, T-Mobile (TMUS) said it was retiring over 1,000 older plans, shifting customers to newer offerings at an added cost of as much as $6 per line per month. And starting in August, AT&T (T) hiked rates on some of its older plans by $10 to $20 and increased a monthly per-line fee by $1.
The changes contributed to a steep 5.9% jump in Americans' wireless bills from July to August alone, according to Consumer Price Index data. It was the largest single-month jump since the Bureau of Labor Statistics began tracking the category nearly three decades ago.
In a twist, last month's rising phone bills may have helped convince the Federal Reserve to implement its first interest rate hike in three years. The steep price jump likely contributed about 10 basis points of August's 0.3% month-over-month rise in core consumer prices, according to Wall Street ******* ysts. The hotter-than-expected jump in this category, which strips out price changes in the particularly volatile food and energy sectors, helped cement expectations for the Fed's 25 basis point hike to benchmark rates last Wednesday.
Read more: How the Fed rate decision affects your bank accounts, loans, credit cards, and investments
#august #plans
In late June, T-Mobile (TMUS) said it was retiring over 1,000 older plans, shifting customers to newer offerings at an added cost of as much as $6 per line per month. And starting in August, AT&T (T) hiked rates on some of its older plans by $10 to $20 and increased a monthly per-line fee by $1.
The changes contributed to a steep 5.9% jump in Americans' wireless bills from July to August alone, according to Consumer Price Index data. It was the largest single-month jump since the Bureau of Labor Statistics began tracking the category nearly three decades ago.
In a twist, last month's rising phone bills may have helped convince the Federal Reserve to implement its first interest rate hike in three years. The steep price jump likely contributed about 10 basis points of August's 0.3% month-over-month rise in core consumer prices, according to Wall Street ******* ysts. The hotter-than-expected jump in this category, which strips out price changes in the particularly volatile food and energy sectors, helped cement expectations for the Fed's 25 basis point hike to benchmark rates last Wednesday.
Read more: How the Fed rate decision affects your bank accounts, loans, credit cards, and investments
#august #plans
1 month ago
Millions of Americans recently received unwelcome news about their cell phone bills.
In late June, T-Mobile (TMUS) said it was retiring over 1,000 older plans, shifting customers to newer offerings at an added cost of as much as $6 per line per month. And starting in August, AT&T (T) hiked rates on some of its older plans by $10 to $20 and increased a monthly per-line fee by $1.
The changes contributed to a steep 5.9% jump in Americans' wireless bills from July to August alone, according to Consumer Price Index data. It was the largest single-month jump since the Bureau of Labor Statistics began tracking the category nearly three decades ago.
In a twist, last month's rising phone bills may have helped convince the Federal Reserve to implement its first interest rate hike in three years. The steep price jump likely contributed about 10 basis points of August's 0.3% month-over-month rise in core consumer prices, according to Wall Street ******* ysts. The hotter-than-expected jump in this category, which strips out price changes in the particularly volatile food and energy sectors, helped cement expectations for the Fed's 25 basis point hike to benchmark rates last Wednesday.
Read more: How the Fed rate decision affects your bank accounts, loans, credit cards, and investments
#Consumer
In late June, T-Mobile (TMUS) said it was retiring over 1,000 older plans, shifting customers to newer offerings at an added cost of as much as $6 per line per month. And starting in August, AT&T (T) hiked rates on some of its older plans by $10 to $20 and increased a monthly per-line fee by $1.
The changes contributed to a steep 5.9% jump in Americans' wireless bills from July to August alone, according to Consumer Price Index data. It was the largest single-month jump since the Bureau of Labor Statistics began tracking the category nearly three decades ago.
In a twist, last month's rising phone bills may have helped convince the Federal Reserve to implement its first interest rate hike in three years. The steep price jump likely contributed about 10 basis points of August's 0.3% month-over-month rise in core consumer prices, according to Wall Street ******* ysts. The hotter-than-expected jump in this category, which strips out price changes in the particularly volatile food and energy sectors, helped cement expectations for the Fed's 25 basis point hike to benchmark rates last Wednesday.
Read more: How the Fed rate decision affects your bank accounts, loans, credit cards, and investments
#Consumer
1 month ago
Experienced investors know the advantages of buying and holding S&P 500 index funds like the Vanguard S&P 500 ETF (NYSEMKT: VOO) or the SPDR S&P 500 ETF Trust (NYSEMKT: SPY). Not only are they super simple, but statistically speaking, you're likely to get better performance from them than you are by picking individual stocks or by owning an actively managed fund.
Nevertheless, given its long-term (and often market-beating) track record, even the most disciplined of investors might have the itch to step into a stake in Berkshire Hathaway (NYSE: BRKA) (NYSE: BRKB). But is it actually the better buy?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Berkshire Hathaway is a conglomerate consisting of several dozen reliable cash-producing businesses as well as a portfolio of hand-picked stocks. Brought to prominence by Warren Buffett, the company's flexible structure has enabled its shares to consistently outperform the S&P 500 since Buffett first took the helm in 1965.
It hasn't beaten the market every year since then, to be clear. Some years it did. Other years it didn't. It typically achieved the feat in five-year time frames.
#signal #years #buffett #flashing
Nevertheless, given its long-term (and often market-beating) track record, even the most disciplined of investors might have the itch to step into a stake in Berkshire Hathaway (NYSE: BRKA) (NYSE: BRKB). But is it actually the better buy?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Berkshire Hathaway is a conglomerate consisting of several dozen reliable cash-producing businesses as well as a portfolio of hand-picked stocks. Brought to prominence by Warren Buffett, the company's flexible structure has enabled its shares to consistently outperform the S&P 500 since Buffett first took the helm in 1965.
It hasn't beaten the market every year since then, to be clear. Some years it did. Other years it didn't. It typically achieved the feat in five-year time frames.
#signal #years #buffett #flashing
1 month ago
Millions of Americans recently received unwelcome news about their cell phone bills.
In late June, T-Mobile (TMUS) said it was retiring over 1,000 older plans, shifting customers to newer offerings at an added cost of as much as $6 per line per month. And starting in August, AT&T (T) hiked rates on some of its older plans by $10 to $20 and increased a monthly per-line fee by $1.
The changes contributed to a steep 5.9% jump in Americans' wireless bills from July to August alone, according to Consumer Price Index data. It was the largest single-month jump since the Bureau of Labor Statistics began tracking the category nearly three decades ago.
In a twist, last month's rising phone bills may have helped convince the Federal Reserve to implement its first interest rate hike in three years. The steep price jump likely contributed about 10 basis points of August's 0.3% month-over-month rise in core consumer prices, according to Wall Street ***** ysts. The hotter-than-expected jump in this category, which strips out price changes in the particularly volatile food and energy sectors, helped cement expectations for the Fed's 25 basis point hike to benchmark rates last Wednesday.
Read more: How the Fed rate decision affects your bank accounts, loans, credit cards, and investments
#month #americans #august #older
In late June, T-Mobile (TMUS) said it was retiring over 1,000 older plans, shifting customers to newer offerings at an added cost of as much as $6 per line per month. And starting in August, AT&T (T) hiked rates on some of its older plans by $10 to $20 and increased a monthly per-line fee by $1.
The changes contributed to a steep 5.9% jump in Americans' wireless bills from July to August alone, according to Consumer Price Index data. It was the largest single-month jump since the Bureau of Labor Statistics began tracking the category nearly three decades ago.
In a twist, last month's rising phone bills may have helped convince the Federal Reserve to implement its first interest rate hike in three years. The steep price jump likely contributed about 10 basis points of August's 0.3% month-over-month rise in core consumer prices, according to Wall Street ***** ysts. The hotter-than-expected jump in this category, which strips out price changes in the particularly volatile food and energy sectors, helped cement expectations for the Fed's 25 basis point hike to benchmark rates last Wednesday.
Read more: How the Fed rate decision affects your bank accounts, loans, credit cards, and investments
#month #americans #august #older
1 month ago
On September 8, 2026, CNBC reported that Novartis' failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY), both of which are racing to prove that lowering lipoprotein(a), or Lp(a). It can meaningfully reduce heart attacks and strokes.
Analysts said Amgen's olpasiran faces the clearest negative read-through given its similar trial design. Lilly's lepodisiran is being tested in a broader patient population that could limit how directly Novartis' failure applies. It is also described as less material to Lilly's overall valuation than pelacarsen was for Novartis.
Copyright: stocking / 123RF Stock Photo
Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY) could still succeed where Novartis failed. Pelacarsen's failure does not establish that lowering Lp(a) cannot reduce cardiovascular events. **** ysts noted that Novartis' trial faced a high statistical hurdle and that Amgen's olpasiran and Lilly's lepodisiran have produced stronger Lp(a) reductions in earlier studies. Both companies also continue testing their drugs in specific patient populations with high Lp(a). It leaves room for their trials to produce different outcomes from Novartis' study.
Lilly's lepodisiran faces a less direct read-through than Amgen's olpasiran. **** ysts view Amgen's olpasiran as the closest comparison to pelacarsen because the programs use similar trial designs. Lilly's lepodisiran is being tested in an overall patient population. It could make Novartis' failure less directly applicable. **** ysts also view lepodisiran as less material to Lilly's overall valuation than pelacarsen was to Novartis. It reduces the potential financial impact of an unsuccessful outcome.
#lepodisiran #less
Analysts said Amgen's olpasiran faces the clearest negative read-through given its similar trial design. Lilly's lepodisiran is being tested in a broader patient population that could limit how directly Novartis' failure applies. It is also described as less material to Lilly's overall valuation than pelacarsen was for Novartis.
Copyright: stocking / 123RF Stock Photo
Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY) could still succeed where Novartis failed. Pelacarsen's failure does not establish that lowering Lp(a) cannot reduce cardiovascular events. **** ysts noted that Novartis' trial faced a high statistical hurdle and that Amgen's olpasiran and Lilly's lepodisiran have produced stronger Lp(a) reductions in earlier studies. Both companies also continue testing their drugs in specific patient populations with high Lp(a). It leaves room for their trials to produce different outcomes from Novartis' study.
Lilly's lepodisiran faces a less direct read-through than Amgen's olpasiran. **** ysts view Amgen's olpasiran as the closest comparison to pelacarsen because the programs use similar trial designs. Lilly's lepodisiran is being tested in an overall patient population. It could make Novartis' failure less directly applicable. **** ysts also view lepodisiran as less material to Lilly's overall valuation than pelacarsen was to Novartis. It reduces the potential financial impact of an unsuccessful outcome.
#lepodisiran #less
1 month ago
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
U.S. household income rose to a record high in 2025, but gains remained uneven across the income distribution, with higher-income households seeing an increase while the lowest-income group showed no statistically significant change.
The U.S. Census Bureau released its 2025 income, poverty and health insurance findings on Tuesday, showing real median household income increased 2.6% to $87,460, from the 2024 estimate of $85,210. It was the highest level since records began in 1967.
Don't Miss:
Think Your 'Safe' Stocks Protect You? You're Ignoring the Real Growth Triggers — Here's What to Add Now
#real #finance #bureau #don 't
U.S. household income rose to a record high in 2025, but gains remained uneven across the income distribution, with higher-income households seeing an increase while the lowest-income group showed no statistically significant change.
The U.S. Census Bureau released its 2025 income, poverty and health insurance findings on Tuesday, showing real median household income increased 2.6% to $87,460, from the 2024 estimate of $85,210. It was the highest level since records began in 1967.
Don't Miss:
Think Your 'Safe' Stocks Protect You? You're Ignoring the Real Growth Triggers — Here's What to Add Now
#real #finance #bureau #don 't
1 month ago
Evommune, Inc. (NYSE:EVMN) announced on September 8 that EVO756 missed its primary endpoint in a randomized, double-blind, placebo-controlled Phase 2b trial involving 121 adults with moderate-to-severe atopic dermatitis. The primary measure was the percentage change from baseline in Eczema Area and Severity Index, or EASI, at week 12. No tested dose met the primary or secondary endpoints, and development in that indication will stop.
Evommune, Inc. (NYSE:EVMN) had already discontinued EVO756 for chronic spontaneous urticaria following a June trial failure. Development continues in migraine prevention. The setbacks place greater weight on EVO301, which has positive Phase 2a eczema data and a Phase 2b study planned for mid-2027.
Evommune, Inc. (NYSE:EVMN) has clinical evidence supporting its next eczema program. In February, the company reported that EVO301 met the primary endpoint in a randomized, double-blind, placebo-controlled Phase 2a trial involving 70 adults. Participants received two intravenous doses or placebo over a 12-week study.
Evommune, Inc. (NYSE:EVMN) reported a 55% EASI reduction with EVO301 versus 22% with placebo at week 12, a difference of 33 percentage points. The study met its prespecified Bayesian success criterion, and a separate conventional ****** ysis showed statistical significance at p
Evommune, Inc. (NYSE:EVMN) had already discontinued EVO756 for chronic spontaneous urticaria following a June trial failure. Development continues in migraine prevention. The setbacks place greater weight on EVO301, which has positive Phase 2a eczema data and a Phase 2b study planned for mid-2027.
Evommune, Inc. (NYSE:EVMN) has clinical evidence supporting its next eczema program. In February, the company reported that EVO301 met the primary endpoint in a randomized, double-blind, placebo-controlled Phase 2a trial involving 70 adults. Participants received two intravenous doses or placebo over a 12-week study.
Evommune, Inc. (NYSE:EVMN) reported a 55% EASI reduction with EVO301 versus 22% with placebo at week 12, a difference of 33 percentage points. The study met its prespecified Bayesian success criterion, and a separate conventional ****** ysis showed statistical significance at p
1 month ago
Updated on: September 16, 2026 / 5:45 PM EDT / CBS/AP
Scientists have discovered a crater on the moon that's bigger than the Roman Colosseum and is the result of a powerful impact two years ago that initially went undetected.
The steep-sided hole measured about 728 feet across, the length of two football fields, and up to 141 feet deep, equivalent to three vertically stacked yellow school buses, according to NASA. It's the solar system's biggest known impact crater carved out in recent times.
Such a large-scale event is estimated to occur only once every 132 years, researchers said, making this a treasure trove of information as NASA prepares to build a base for astronauts on the moon.
"This event constitutes a statistically rare, effectively once-in-a-lifetime observation," the scientists wrote in one of two studies appearing on the subject Wednesday in the journal Science Advances.
#crater
Scientists have discovered a crater on the moon that's bigger than the Roman Colosseum and is the result of a powerful impact two years ago that initially went undetected.
The steep-sided hole measured about 728 feet across, the length of two football fields, and up to 141 feet deep, equivalent to three vertically stacked yellow school buses, according to NASA. It's the solar system's biggest known impact crater carved out in recent times.
Such a large-scale event is estimated to occur only once every 132 years, researchers said, making this a treasure trove of information as NASA prepares to build a base for astronauts on the moon.
"This event constitutes a statistically rare, effectively once-in-a-lifetime observation," the scientists wrote in one of two studies appearing on the subject Wednesday in the journal Science Advances.
#crater
1 month ago
Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies' experimental Lyme disease vaccine candidate, and will now begin the official review.
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
#vaccine #pfizer #NYSE
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
#vaccine #pfizer #NYSE
1 month ago
Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies' experimental Lyme disease vaccine candidate, and will now begin the official review.
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
#disease
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
#disease
1 month ago
It was a nail biter, but the San Diego Padres came away from it with a seven-game win streak and back-to-back sweeps for the third time this season. It was a great game to cap off the sweep. Ethan Salas finally notched his first big-league hit with a triple in Oracle Park, Fernando Tatis Jr. went 3-for-4 with two RBI and Manny Machado launched his 27th home run of the season.
The Friars will now turn to the Colorado Rockies to round out their penultimate road trip of the 2026 season. It's a four-game set in the hitter-friendly environs of Coors Field. With the way the Padres have been swinging their bats lately (37 runs in their last six games; 6.2 runs per game), they should have no problem keeping the good vibes rolling.
Sugano has been surprisingly good in the hitter-friendly confines of Coors Field. That said, he's still pitched to a 5.30 ERA. But that number goes down to 4.96 at home compared to 5.64 away. It's an interesting split to have when Colorado is known for being a hitter's dream.
The righty has been particularly awful recently. In his last seven starts, Sugano has pitched to a 7.71 ERA across 35 innings pitched. In his last three starts, he's surrendered a whopping 14 runs (16.0 IP). If San Diego's recently potent lineup can take advantage of that, they would be well on their way to their eighth straight win.
Since joining the Padres, it's no secret that Mize has struggled. He's posted a dismal 6.34 ERA in his first seven games. Much of that is believed to be due to a groin injury that Mize has been pitching through. It was reported earlier this week that that injury was the reason many scouts decided against Mize, lowering his trade stock.
#game #runs #last #Colorado
The Friars will now turn to the Colorado Rockies to round out their penultimate road trip of the 2026 season. It's a four-game set in the hitter-friendly environs of Coors Field. With the way the Padres have been swinging their bats lately (37 runs in their last six games; 6.2 runs per game), they should have no problem keeping the good vibes rolling.
Sugano has been surprisingly good in the hitter-friendly confines of Coors Field. That said, he's still pitched to a 5.30 ERA. But that number goes down to 4.96 at home compared to 5.64 away. It's an interesting split to have when Colorado is known for being a hitter's dream.
The righty has been particularly awful recently. In his last seven starts, Sugano has pitched to a 7.71 ERA across 35 innings pitched. In his last three starts, he's surrendered a whopping 14 runs (16.0 IP). If San Diego's recently potent lineup can take advantage of that, they would be well on their way to their eighth straight win.
Since joining the Padres, it's no secret that Mize has struggled. He's posted a dismal 6.34 ERA in his first seven games. Much of that is believed to be due to a groin injury that Mize has been pitching through. It was reported earlier this week that that injury was the reason many scouts decided against Mize, lowering his trade stock.
#game #runs #last #Colorado
1 month ago
Texas volleyball has shown flashes of brilliance through the first three weeks of the season.
It has been swept (Louisville, Nebraska) and it brought out the brooms themselves (TCU, USC). The Longhorns won the fourth set against No. 8 SMU 28-26, but ended up losing the match in the fifth set.
The final game before conference play was a 3-1 win against No. 6 Wisconsin and it is probably, statistically, Texas' best game. Head coach Jerritt Elliott called it "the most organized and dialed-in that we've been all season long.
"We've had about three and a half total practices, so we're just trying to kind of get a rhythm," Elliott said after the match Sunday afternoon.
The Longhorns found it against the team that eliminated them from the NCAA Tournament last season in their most complete game yet.
#game #longhorns #we 've
It has been swept (Louisville, Nebraska) and it brought out the brooms themselves (TCU, USC). The Longhorns won the fourth set against No. 8 SMU 28-26, but ended up losing the match in the fifth set.
The final game before conference play was a 3-1 win against No. 6 Wisconsin and it is probably, statistically, Texas' best game. Head coach Jerritt Elliott called it "the most organized and dialed-in that we've been all season long.
"We've had about three and a half total practices, so we're just trying to kind of get a rhythm," Elliott said after the match Sunday afternoon.
The Longhorns found it against the team that eliminated them from the NCAA Tournament last season in their most complete game yet.
#game #longhorns #we 've
2 months ago
Toward the end of the lightning round on September 8, when a caller inquired about AstraZeneca PLC (NYSE:AZN), Mad Money host Jim Cramer commented:
Alright, now, AstraZeneca reminds me of a company, it's not unlike Novartis. I'm a little nervous about it. It's been missing some of its trials. I don't think COPD is enough to change my mind… I am not going to put my money on AstraZeneca.
AstraZeneca PLC (NYSE:AZN) maintains a solid financial foundation supported by steady top-line growth and disciplined cost management. In its second-quarter report, the company generated total revenue of $15.38 billion, marking a 6.4% increase compared to the same period last year. Adjusted earnings per share reached $2.63, outperforming ****** yst consensus estimates.
The profitability was driven by strong global demand for core oncology and rare disease treatments, which successfully offset revenue headwinds from generic competition affecting older blockbusters like Farxiga and Brilinta. With a net margin hovering around 17.02% and management reiterating its full-year guidance for mid-to-high single-digit revenue growth along with low double-digit core EPS expansion, the core business continues to demonstrate commercial resilience.
The primary driver behind the skepticism could be based on tangible execution risks and regulatory hurdles that threaten AstraZeneca PLC's (NYSE:AZN) long-term top line. A significant blow to the rare disease division came when anselamimab failed to achieve statistical significance for the primary endpoint in the overall AL amyloidosis population in the Phase III CARES program, although AstraZeneca reported encouraging results in a prespecified subgroup of patients with kappa light-chain amyloidosis.
#management
Alright, now, AstraZeneca reminds me of a company, it's not unlike Novartis. I'm a little nervous about it. It's been missing some of its trials. I don't think COPD is enough to change my mind… I am not going to put my money on AstraZeneca.
AstraZeneca PLC (NYSE:AZN) maintains a solid financial foundation supported by steady top-line growth and disciplined cost management. In its second-quarter report, the company generated total revenue of $15.38 billion, marking a 6.4% increase compared to the same period last year. Adjusted earnings per share reached $2.63, outperforming ****** yst consensus estimates.
The profitability was driven by strong global demand for core oncology and rare disease treatments, which successfully offset revenue headwinds from generic competition affecting older blockbusters like Farxiga and Brilinta. With a net margin hovering around 17.02% and management reiterating its full-year guidance for mid-to-high single-digit revenue growth along with low double-digit core EPS expansion, the core business continues to demonstrate commercial resilience.
The primary driver behind the skepticism could be based on tangible execution risks and regulatory hurdles that threaten AstraZeneca PLC's (NYSE:AZN) long-term top line. A significant blow to the rare disease division came when anselamimab failed to achieve statistical significance for the primary endpoint in the overall AL amyloidosis population in the Phase III CARES program, although AstraZeneca reported encouraging results in a prespecified subgroup of patients with kappa light-chain amyloidosis.
#management
2 months ago
Consumers just can't catch a break. According to Friday's Consumer Price Index report from the Bureau of Labor Statistics (BLS), inflation is holding steady as surging gas prices empty shoppers' wallets.
But that's not all. Year-over-year data about household debt paints a dim picture of the state of consumer finances. However, this week's home sales report offers a silver lining, showing it might be a good time to buy a house.
More from WWD
Back-to-School Resale Meets Its Toughest Customer: Children
Cautious Consumers Seen Spending More this Holiday Shopping Season
#consumers #report #price
But that's not all. Year-over-year data about household debt paints a dim picture of the state of consumer finances. However, this week's home sales report offers a silver lining, showing it might be a good time to buy a house.
More from WWD
Back-to-School Resale Meets Its Toughest Customer: Children
Cautious Consumers Seen Spending More this Holiday Shopping Season
#consumers #report #price
2 months ago
This one started bowling shoe ugly and ended up Sam the Chinese Crested Dog ugly, with Bradley Hanner proving why he is the definition of the 26th man on a Major League roster. Gerrit Cole gave up more home runs, three of em while not making it out of the fifth inning, but Hanner wasn't any better, allowing two dingers while five men crossed the plate against him. All this is to say the Yankees were kicked around Saturday afternoon, losing 12-2 to the Mets
I don't know what it is about Gerrit Cole. He's always been a little bit homer ***** e, especially since coming to Yankee Stadium. Fastballs in the zone lead to some kinds of nasty contact, but the thing that's really been different about him since returning from Tommy John is how many pitches he's keeping in the zone. He's got the lowest walk rate of his career, and indeed he didn't walk a single batter today. He also has the highest Zone%, or, throws more pitches in the strike zone than any other season of his career.
In his last two starts he's allowed seven home runs. Only three today, though they still counted for four runs like last weekend against the Padres.
Part of this is just random variance, enough monkeys at enough typewriters for long enough. Any time you talk about two games' worth of data, you have to throw up your hands at the universe. He's also been stung by Fernando Tatis Jr., Manny Machado, Jake Cronenworth, Francisco Lindor…guys that have been around the block. Lindor especially looked keyed up to swing in the game's first AB, the first dinger Cole allowed today. Former Baby Bomber Luis Torrens and rookie Carson Benge also homered off Cole to build a 4-0 lead.
View Link
#today #enough #lindor
I don't know what it is about Gerrit Cole. He's always been a little bit homer ***** e, especially since coming to Yankee Stadium. Fastballs in the zone lead to some kinds of nasty contact, but the thing that's really been different about him since returning from Tommy John is how many pitches he's keeping in the zone. He's got the lowest walk rate of his career, and indeed he didn't walk a single batter today. He also has the highest Zone%, or, throws more pitches in the strike zone than any other season of his career.
In his last two starts he's allowed seven home runs. Only three today, though they still counted for four runs like last weekend against the Padres.
Part of this is just random variance, enough monkeys at enough typewriters for long enough. Any time you talk about two games' worth of data, you have to throw up your hands at the universe. He's also been stung by Fernando Tatis Jr., Manny Machado, Jake Cronenworth, Francisco Lindor…guys that have been around the block. Lindor especially looked keyed up to swing in the game's first AB, the first dinger Cole allowed today. Former Baby Bomber Luis Torrens and rookie Carson Benge also homered off Cole to build a 4-0 lead.
View Link
#today #enough #lindor
2 months ago
NEW DELHI: England completed a 3-0 Test series clean sweep over Pakistan at Edgbaston, but the series produced an unusual statistic.
It was only the eighth three-match Test series in history to finish without a single individual century. It was also only the second such series in England, after the 1888 Ashes.
England's batting was led by Joe Root, who remained unbeaten on 62 in the third Test, while Jordan **** scored an unbeaten 59 as England chased down 130 with eight wickets in hand.
The result gave England their second 3-0 Test series clean sweep over Pakistan, after their success in the 2022/23 series. It was also England's 15th three-match Test series sweep overall.
For Pakistan, it was their 11th Test series defeat by a 3-0 margin.
England's chase got off to a shocking start when Ben Duckett was dismissed for a duck with the first ball. Emilio Gay then fell later in the same over bowled by Mohammad Abbas.
At 2 for 2, Pakistan had a chance to put England under serious pressure.
But Root settled things down. He survived a major scare when Mohammad Ali bowled him for 23, only for the delivery to be called a no-ball.
It was Ali's 17th no-ball of the series.
Root had another lucky escape when, on 38, he edged Abbas between first and second slip. Neither fielder went for the catch.
The England batter made Pakistan pay for the missed opportunities. He went on to complete his 110th score of 50 or more in Test cricket, including 41 centuries.
Jordan **** provided excellent support for Root as the pair took control of the chase.
Cox remained unbeaten on 59 and helped England reach the target in just 25 overs.
Pakistan had shown plenty of fight in the third Test after conceding a massive 320-run first-innings lead. But England's dominance in the first two Tests meant the series was already heavily tilted in their favour.
Had Pakistan shown the same fight earlier in the series, the contest could have been much closer.
England's fast bowlers were the biggest difference between the two sides.
Ollie Robinson led the attack and finished the series with 21 wickets. Jofra Archer, Josh Tongue and Gus Atkinson also played important roles as England's pace attack made the most of helpful conditions.
The batting, however, was less convincing.
No England batter scored a century across the three Tests, making the series only the eighth three-match Test series without an individual hundred and just the second in England after the 1888 Ashes.
Pakistan's biggest positive came from debutant Razaullah, who produced an exciting counter-attack at Edgbaston.
His thrilling 81 off 63 **** gave Pakistan hope and briefly brought the third Test to life.
But it was too late to change the outcome of the series.
Pakistan have now lost 16 of their 21 Tests. Their difficult tour was followed by major changes, with seven players replaced in the squad after the second Test and coach Sarfaraz Ahmed and his **** istant
It was only the eighth three-match Test series in history to finish without a single individual century. It was also only the second such series in England, after the 1888 Ashes.
England's batting was led by Joe Root, who remained unbeaten on 62 in the third Test, while Jordan **** scored an unbeaten 59 as England chased down 130 with eight wickets in hand.
The result gave England their second 3-0 Test series clean sweep over Pakistan, after their success in the 2022/23 series. It was also England's 15th three-match Test series sweep overall.
For Pakistan, it was their 11th Test series defeat by a 3-0 margin.
England's chase got off to a shocking start when Ben Duckett was dismissed for a duck with the first ball. Emilio Gay then fell later in the same over bowled by Mohammad Abbas.
At 2 for 2, Pakistan had a chance to put England under serious pressure.
But Root settled things down. He survived a major scare when Mohammad Ali bowled him for 23, only for the delivery to be called a no-ball.
It was Ali's 17th no-ball of the series.
Root had another lucky escape when, on 38, he edged Abbas between first and second slip. Neither fielder went for the catch.
The England batter made Pakistan pay for the missed opportunities. He went on to complete his 110th score of 50 or more in Test cricket, including 41 centuries.
Jordan **** provided excellent support for Root as the pair took control of the chase.
Cox remained unbeaten on 59 and helped England reach the target in just 25 overs.
Pakistan had shown plenty of fight in the third Test after conceding a massive 320-run first-innings lead. But England's dominance in the first two Tests meant the series was already heavily tilted in their favour.
Had Pakistan shown the same fight earlier in the series, the contest could have been much closer.
England's fast bowlers were the biggest difference between the two sides.
Ollie Robinson led the attack and finished the series with 21 wickets. Jofra Archer, Josh Tongue and Gus Atkinson also played important roles as England's pace attack made the most of helpful conditions.
The batting, however, was less convincing.
No England batter scored a century across the three Tests, making the series only the eighth three-match Test series without an individual hundred and just the second in England after the 1888 Ashes.
Pakistan's biggest positive came from debutant Razaullah, who produced an exciting counter-attack at Edgbaston.
His thrilling 81 off 63 **** gave Pakistan hope and briefly brought the third Test to life.
But it was too late to change the outcome of the series.
Pakistan have now lost 16 of their 21 Tests. Their difficult tour was followed by major changes, with seven players replaced in the squad after the second Test and coach Sarfaraz Ahmed and his **** istant
2 months ago
LeBron James has spent more than two decades setting records that once looked out of reach. Yet former NBA center Olden Polynice believes one of the game's rare statistical feats should have belonged to James long before Russell Westbrook made it his own.
Polynice is not questioning James' greatness. His argument is almost the opposite. He believes James had so much size and all-around ability that failing to post a full-season triple-double stands out as a strange omission from an otherwise historic career.
Speaking on SiriusXM NBA Radio, Polynice said James should have reached the milestone before Westbrook ever did. He pointed to James' unusual combination of strength, skill and playmaking as the reason.
Jan 31, 2023; New York, New York, USA; Los Angeles Lakers forward LeBron James (6) and guard Russell Westbrook (0) react during overtime against the New York Knicks at Madison Square Garden. Mandatory Credit: Brad Penner-USA TODAY Sports
"I love LeBron. I really do. I think he's one of the greatest ever. Ever," Polynice said. "What he's doing right now we've never seen before. And I won't even get into the off the court. He's by himself over there."
#james #lebron
Polynice is not questioning James' greatness. His argument is almost the opposite. He believes James had so much size and all-around ability that failing to post a full-season triple-double stands out as a strange omission from an otherwise historic career.
Speaking on SiriusXM NBA Radio, Polynice said James should have reached the milestone before Westbrook ever did. He pointed to James' unusual combination of strength, skill and playmaking as the reason.
Jan 31, 2023; New York, New York, USA; Los Angeles Lakers forward LeBron James (6) and guard Russell Westbrook (0) react during overtime against the New York Knicks at Madison Square Garden. Mandatory Credit: Brad Penner-USA TODAY Sports
"I love LeBron. I really do. I think he's one of the greatest ever. Ever," Polynice said. "What he's doing right now we've never seen before. And I won't even get into the off the court. He's by himself over there."
#james #lebron
2 months ago
It was great to hear Dave Burns and John Gambadoro Friday afternoon on ArizonaSports 98.7 FM when they mentioned my story about the Arizona Cardinals potentially shocking the world this season.
Their discussion morphed into what they believed the Cardinals would have to do to "shock the world." Different thoughts were expressed, including not being one of the five worst teams in the league. In another, it was said the offense would shock the world if they ranked in the top 10.
To that end, I've always taken exception to the rankings as gospel mantra that usually takes place in a vacuum. By that I mean, ranking whatever number it is in yards or points, for example, is meaningless unless it takes into account the actual statistics for other teams in the rankings.
Last season, the Denver Broncos were 10th in total yards at 342.7 per game and 14th in points per game (23.6 average). The Baltimore Ravens were 16th (smack dab in the middle of the 32-team league) in yards at 332.2 per game and 11th in points (24.9 per game). The Kansas City Chiefs were 20th in yards (320.7 average) and 21st in points (21.3).
It's easy to see that the difference in yards per game between the Broncos and Ravens (seven ranking spots) was only 10.5 per game and 22.0 per game between the Broncos and Chiefs (11 spots).
#game #yards #points #World
Their discussion morphed into what they believed the Cardinals would have to do to "shock the world." Different thoughts were expressed, including not being one of the five worst teams in the league. In another, it was said the offense would shock the world if they ranked in the top 10.
To that end, I've always taken exception to the rankings as gospel mantra that usually takes place in a vacuum. By that I mean, ranking whatever number it is in yards or points, for example, is meaningless unless it takes into account the actual statistics for other teams in the rankings.
Last season, the Denver Broncos were 10th in total yards at 342.7 per game and 14th in points per game (23.6 average). The Baltimore Ravens were 16th (smack dab in the middle of the 32-team league) in yards at 332.2 per game and 11th in points (24.9 per game). The Kansas City Chiefs were 20th in yards (320.7 average) and 21st in points (21.3).
It's easy to see that the difference in yards per game between the Broncos and Ravens (seven ranking spots) was only 10.5 per game and 22.0 per game between the Broncos and Chiefs (11 spots).
#game #yards #points #World
2 months ago
LeBron James has faced criticism throughout his basketball career. On Friday, former NBA lottery pick Olden Polynice took aim at LBJ for falling short of a certain statistical feat.
Appearing on SiriusXM NBA Radio, Polynice (who was drafted eighth overall by the Chicago Bulls in 1987) gave James his props but proceeded to chastise the 22-time NBA All-Star.
"I love LeBron. I really do. I think he's one of the greatest ever… But, at the same time, I can still be critical of him on some things. One in particular: I thought LeBron should have averaged a triple-double way before Russell Westbrook. That's my personal opinion."
Polynice, who transitioned to coaching after playing 15 seasons in the NBA, went on to make an explosive claim about LBJ's career.
"Believe it or not, this is going to be the weirdest thing ever uttered. I believe LeBron James underachieved."
#believe
Appearing on SiriusXM NBA Radio, Polynice (who was drafted eighth overall by the Chicago Bulls in 1987) gave James his props but proceeded to chastise the 22-time NBA All-Star.
"I love LeBron. I really do. I think he's one of the greatest ever… But, at the same time, I can still be critical of him on some things. One in particular: I thought LeBron should have averaged a triple-double way before Russell Westbrook. That's my personal opinion."
Polynice, who transitioned to coaching after playing 15 seasons in the NBA, went on to make an explosive claim about LBJ's career.
"Believe it or not, this is going to be the weirdest thing ever uttered. I believe LeBron James underachieved."
#believe
2 months ago
After four big wins in the quarterfinals, the United States, France, Spain, and Germany all earned their spots in the semifinals. Saturday's two matchups will be intense. Each team left in the competition can find its way to the finals. Let's take a look at the two semifinal games.
France has been putting up insane statistics during this tournament. Between breaking the single-game three-point record and heavily outscoring their opponents, it is safe to say they are the team to beat. However, this semifinal clash against Germany, who have home-court advantage, will be their biggest test of the tournament.
The good news for France is their depth. There are many strong players who have been coming off the bench and making an impact. One of those players is none other than Marine Johannès. Johannès ranks eighth in the tournament in points scored per game with 16.5. She is currently leading the tournament with 16 three-pointers made so far. Once again, Johannès is not starting in games and making a strong impact each time.
August 15, 2026; Uncasville, Connecticut, USA; New York Liberty guard Marine Johannes (23) shoots the ball against the Connecticut Sun during the second half at Mohegan Sun Arena. Mandatory Credit: Eric Canha-Imagn Images
Meanwhile, starter Gabby Williams has been playing some of her best basketball in the World Cup. If she continues this strong play, France has a strong chance to make it into the finals.
#connecticut
France has been putting up insane statistics during this tournament. Between breaking the single-game three-point record and heavily outscoring their opponents, it is safe to say they are the team to beat. However, this semifinal clash against Germany, who have home-court advantage, will be their biggest test of the tournament.
The good news for France is their depth. There are many strong players who have been coming off the bench and making an impact. One of those players is none other than Marine Johannès. Johannès ranks eighth in the tournament in points scored per game with 16.5. She is currently leading the tournament with 16 three-pointers made so far. Once again, Johannès is not starting in games and making a strong impact each time.
August 15, 2026; Uncasville, Connecticut, USA; New York Liberty guard Marine Johannes (23) shoots the ball against the Connecticut Sun during the second half at Mohegan Sun Arena. Mandatory Credit: Eric Canha-Imagn Images
Meanwhile, starter Gabby Williams has been playing some of her best basketball in the World Cup. If she continues this strong play, France has a strong chance to make it into the finals.
#connecticut
2 months ago
Former Australia opener David Warner found himself in a playful social media exchange with England's famous fan group, the Barmy Army, on Friday, and the banter quickly moved from Saim Ayub's ducks to Marnus Labuschagne's century drought, England's curfew troubles and Warner's long-running Stuart Broad problem.
It all started when the Barmy Army took a dig at Warner after Pakistan batter Saim Ayub registered a pair of ducks in the final Test against England at Edgbaston. The England fan group posted a statistic pointing out that Ayub had now registered a pair twice on English soil.
Replying to the Barmy Army, Warner wrote: "Interesting stat. When was the last time I went 42 innings without a Test hundred??"
The reference was not actually about Warner. The 42 innings was a cheeky dig at former Australia teammate Marnus Labuschagne, who had gone through a lengthy drought without a Test century. Labuschagne's last Test hundred came against England at Headingley in 2023, and his drought had stretched to 42 innings.
But he wasn't finished. Then came the curfew dig.
Warner followed his 42-innings reference with another jab: "Oh do you guys still have a curfew? Asking for a mate."
That was a reference to England's recent off-field disciplinary issues involving players breaking team curfew and going out drinking. The issue had become a talking point around the England setup, with fast bowler Brydon Carse among the players caught up in the recent controversy.
#australia
It all started when the Barmy Army took a dig at Warner after Pakistan batter Saim Ayub registered a pair of ducks in the final Test against England at Edgbaston. The England fan group posted a statistic pointing out that Ayub had now registered a pair twice on English soil.
Replying to the Barmy Army, Warner wrote: "Interesting stat. When was the last time I went 42 innings without a Test hundred??"
The reference was not actually about Warner. The 42 innings was a cheeky dig at former Australia teammate Marnus Labuschagne, who had gone through a lengthy drought without a Test century. Labuschagne's last Test hundred came against England at Headingley in 2023, and his drought had stretched to 42 innings.
But he wasn't finished. Then came the curfew dig.
Warner followed his 42-innings reference with another jab: "Oh do you guys still have a curfew? Asking for a mate."
That was a reference to England's recent off-field disciplinary issues involving players breaking team curfew and going out drinking. The issue had become a talking point around the England setup, with fast bowler Brydon Carse among the players caught up in the recent controversy.
#australia
2 months ago
On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING trial showed that their co-developed severe asthma drug, TEZSPIRE, achieved statistically significant and clinically meaningful improvements across both co-primary endpoints, histologic remission and the frequency/severity of dysphagia, and all key secondary endpoints at week 24 in patients with eosinophilic esophagitis. These benefits were sustained through week 52 across both tested doses, accompanied by a safety profile consistent with its approved indications. While CROSSING highlights their joint R&D success, a closer look at their standalone financial performance reveals distinct growth trajectories.
Both pharmaceutical giants delivered solid Q2 2026 results, but AstraZeneca is showing stronger overall financial momentum. AstraZeneca PLC (NYSE:AZN)'s Q2 revenue increased 6% year over year to $15.38 billion, supported by its Oncology franchise, which grew 18% in H1 to $14.12 billion, and its Rare Disease portfolio, which increased 13%. Core EPS rose 21% to $2.63, beating expectations, while management reaffirmed its full-year 2026 outlook for mid-to-high single-digit revenue growth and low double-digit Core EPS growth.
Amgen Inc. (NASDAQ:AMGN) reported Q2 revenue of $10.1 billion, up 10% year over year, while non-GAAP EPS increased 4% to $6.29. Although its key growth products advanced 26%, mature products faced significant biosimilar pressure, with Prolia revenue declining 32% and XGEVA falling 34%. Amgen nevertheless raised its 2026 revenue guidance midpoint to $39.4 billion.
Overall, AZN holds the financial edge due to stronger EPS growth, broader portfolio momentum, and less exposure to the biosimilar erosion affecting AMGN's mature products.
Amgen's bull case is supported by robust growth in key products, which increased 26%, and $3.5 billion in Q2 free cash flow, providing substantial capital flexibility. Wells Fargo raised its Amgen price target to $435 from $400 on September 4, citing potential upside from HORIZON and pipeline ****** ets such as olpasiran. New Phase III VESALIUS-CV data also showed Repatha reduced the risk of death by 20% in high-risk adults without a prior heart attack or stroke, with heart attack risk reductions emerging as early as six months. However, accelerating biosimilar competition affecting legacy franchises such as Prolia and XGEVA remains a key risk to sustained margin expansion.
#revenue #astrazeneca #increased #products
Both pharmaceutical giants delivered solid Q2 2026 results, but AstraZeneca is showing stronger overall financial momentum. AstraZeneca PLC (NYSE:AZN)'s Q2 revenue increased 6% year over year to $15.38 billion, supported by its Oncology franchise, which grew 18% in H1 to $14.12 billion, and its Rare Disease portfolio, which increased 13%. Core EPS rose 21% to $2.63, beating expectations, while management reaffirmed its full-year 2026 outlook for mid-to-high single-digit revenue growth and low double-digit Core EPS growth.
Amgen Inc. (NASDAQ:AMGN) reported Q2 revenue of $10.1 billion, up 10% year over year, while non-GAAP EPS increased 4% to $6.29. Although its key growth products advanced 26%, mature products faced significant biosimilar pressure, with Prolia revenue declining 32% and XGEVA falling 34%. Amgen nevertheless raised its 2026 revenue guidance midpoint to $39.4 billion.
Overall, AZN holds the financial edge due to stronger EPS growth, broader portfolio momentum, and less exposure to the biosimilar erosion affecting AMGN's mature products.
Amgen's bull case is supported by robust growth in key products, which increased 26%, and $3.5 billion in Q2 free cash flow, providing substantial capital flexibility. Wells Fargo raised its Amgen price target to $435 from $400 on September 4, citing potential upside from HORIZON and pipeline ****** ets such as olpasiran. New Phase III VESALIUS-CV data also showed Repatha reduced the risk of death by 20% in high-risk adults without a prior heart attack or stroke, with heart attack risk reductions emerging as early as six months. However, accelerating biosimilar competition affecting legacy franchises such as Prolia and XGEVA remains a key risk to sustained margin expansion.
#revenue #astrazeneca #increased #products
2 months ago
On September 3, AbbVie Inc. (NYSE:ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (NASDAQ:APGE) for $135.11 per share in cash. The $10.9 billion buyouts immediately fold Apogee's promising inflammatory and immunology (I&I) pipeline into AbbVie's commercial engine. On the exact same day, AbbVie separately reported positive Phase 3 Cervino trial results for its bispecific T-cell engager, etentamig, in relapsed/refractory multiple myeloma. Together, the dual catalysts emphasize how mega-cap pharmaceutical giants are deploying cash flow from legacy franchises to lock in next-generation immunology and oncology ***** ets.
In Q2 2026, AbbVie Inc. (NYSE:ABBV) posted $16.99 billion in net revenue, up 10.2% year over year, while adjusted diluted EPS increased 22.9% to $3.65. Growth was driven by its immunology blockbusters, Skyrizi and Rinvoq, which generated $5.505 billion and $2.525 billion in revenue, respectively, representing growth of 24.4% and 24.5%. These gains more than offset the continued decline in Humira revenue, which fell 35.9% to $756 million amid biosimilar competition. AbbVie reiterated its full-year 2026 adjusted EPS guidance of $13.87–$14.07, including a $0.14 dilutive impact from the Apogee transaction.
As a clinical-stage biotech, Apogee Therapeutics, Inc. (NASDAQ:APGE) generated no product revenue in Q2 2026, while R&D expenses reached $67.3 million and G&A expenses totaled $24.3 million, resulting in a quarterly net loss of $85.9 million. Despite the cash burn, the company maintained a strong liquidity position, with $1.3 billion in cash and marketable securities, alongside a $1.3 billion non-dilutive credit collaboration with Blackstone Life Sciences to support Phase 3 trials of its lead ***** et, zumilokibart.
Financially, AbbVie is vastly superior in immediate cash generation and profitability, whereas Apogee represented pure clinical optionality backed by robust liquidity.
For AbbVie, acquiring Apogee's optimized antibody portfolio, including zumilokibart for atopic dermatitis, strengthens its post-Humira immunology franchise. Combined with internal R&D advances such as etentamig, which achieved statistically significant overall response rate and progression-free survival results in the Phase 3 Cervino study, along with an 87.9% 12-month overall survival rate, AbbVie demonstrates potential to sustain strong organic growth.
#phase #revenue #Growth
In Q2 2026, AbbVie Inc. (NYSE:ABBV) posted $16.99 billion in net revenue, up 10.2% year over year, while adjusted diluted EPS increased 22.9% to $3.65. Growth was driven by its immunology blockbusters, Skyrizi and Rinvoq, which generated $5.505 billion and $2.525 billion in revenue, respectively, representing growth of 24.4% and 24.5%. These gains more than offset the continued decline in Humira revenue, which fell 35.9% to $756 million amid biosimilar competition. AbbVie reiterated its full-year 2026 adjusted EPS guidance of $13.87–$14.07, including a $0.14 dilutive impact from the Apogee transaction.
As a clinical-stage biotech, Apogee Therapeutics, Inc. (NASDAQ:APGE) generated no product revenue in Q2 2026, while R&D expenses reached $67.3 million and G&A expenses totaled $24.3 million, resulting in a quarterly net loss of $85.9 million. Despite the cash burn, the company maintained a strong liquidity position, with $1.3 billion in cash and marketable securities, alongside a $1.3 billion non-dilutive credit collaboration with Blackstone Life Sciences to support Phase 3 trials of its lead ***** et, zumilokibart.
Financially, AbbVie is vastly superior in immediate cash generation and profitability, whereas Apogee represented pure clinical optionality backed by robust liquidity.
For AbbVie, acquiring Apogee's optimized antibody portfolio, including zumilokibart for atopic dermatitis, strengthens its post-Humira immunology franchise. Combined with internal R&D advances such as etentamig, which achieved statistically significant overall response rate and progression-free survival results in the Phase 3 Cervino study, along with an 87.9% 12-month overall survival rate, AbbVie demonstrates potential to sustain strong organic growth.
#phase #revenue #Growth
2 months ago
XRP trades at $1.44, up 40% in 30 days, but remains down 23% year-to-date and needs $1.84 to break even for 2026.
A Senate cloture vote on the CLARITY Act and an FOMC rate decision converge mid-month, but the House canceled September votes, pushing final crypto legislation into a lame-duck session.
The XRP Ledger earned BIS approval for recording official statistics hashes, adding long-term institutional demand context without predicting near-term price moves.
Just released. Our ***** ysts combed the entire stock market and named the ten best stocks to buy right now. The report is free. Enter your email and see if any of your stocks made the cut.
XRP (CRYPTO:XRP) trades at about $1.42 on September 9, 2026, up roughly 38% from its $1.03 close a month ago and about 5.3% from its September 2 close. The move comes just ahead of two major U.S. events: a September 15 Senate cloture vote on the CLARITY Act and the Federal Reserve's September 15–16 policy meeting.
#september #vote
A Senate cloture vote on the CLARITY Act and an FOMC rate decision converge mid-month, but the House canceled September votes, pushing final crypto legislation into a lame-duck session.
The XRP Ledger earned BIS approval for recording official statistics hashes, adding long-term institutional demand context without predicting near-term price moves.
Just released. Our ***** ysts combed the entire stock market and named the ten best stocks to buy right now. The report is free. Enter your email and see if any of your stocks made the cut.
XRP (CRYPTO:XRP) trades at about $1.42 on September 9, 2026, up roughly 38% from its $1.03 close a month ago and about 5.3% from its September 2 close. The move comes just ahead of two major U.S. events: a September 15 Senate cloture vote on the CLARITY Act and the Federal Reserve's September 15–16 policy meeting.
#september #vote
2 months ago
Every ETF.com fund page follows the same simple pattern: etf.com/[TICKER]. Want the Invesco QQQ Trust? Go to etf.com/QQQ. Want the Vanguard S&P 500 ETF? etf.com/VOO. Each page pulls together the fund's real-time market data, fundamentals, holdings, cost, and **** ysis into one place — so you don't have to hunt across a dozen websites to research a fund. Using QQQ as our example, here's what you'll find.
At the top of every fund page is the live quote — the fund's current price, daily change, and an intraday chart showing how it's moved through the trading day. Alongside it you get the essential trading data: previous close, opening price, volume, the day's range, the 52-week range, and real-time bid/ask prices and sizes. This is the information you need to actually place a trade intelligently — especially the bid/ask spread, which tells you how cheaply you can get in and out.
The Summary Data section gives you the fund's vital statistics in seconds: the issuer (who runs the fund), the inception date (how long it's existed), the expense ratio (what it costs you annually), the AUM (assets under management — a proxy for size and liquidity), the index tracked, the segment, and the fund's legal structure. For QQQ, this is where you'd instantly see it's an Invesco fund tracking the Nasdaq-100. These are the first things any investor should check before buying.
One of the most useful features is the Competing ETFs list. Rather than making you research alternatives on your own, the fund page shows you similar funds side by side — with their AUM and expense ratios — so you can immediately see whether a cheaper or larger competitor exists. On the QQQ page, for example, this is where you'd spot alternatives like QQQM. It turns a single-fund lookup into instant comparison shopping.
Right on the page, the built-in Compare ETFs tool lets you pit the fund against any other ticker — QQQ vs. VOO, QQQ vs. QQQM, whatever you choose — and see the differences in cost, holdings, and performance line by line. It's the fastest way to answer the question every ETF investor eventually asks: "Which of these two should I actually buy?"
#page #invesco #qqqm #real
At the top of every fund page is the live quote — the fund's current price, daily change, and an intraday chart showing how it's moved through the trading day. Alongside it you get the essential trading data: previous close, opening price, volume, the day's range, the 52-week range, and real-time bid/ask prices and sizes. This is the information you need to actually place a trade intelligently — especially the bid/ask spread, which tells you how cheaply you can get in and out.
The Summary Data section gives you the fund's vital statistics in seconds: the issuer (who runs the fund), the inception date (how long it's existed), the expense ratio (what it costs you annually), the AUM (assets under management — a proxy for size and liquidity), the index tracked, the segment, and the fund's legal structure. For QQQ, this is where you'd instantly see it's an Invesco fund tracking the Nasdaq-100. These are the first things any investor should check before buying.
One of the most useful features is the Competing ETFs list. Rather than making you research alternatives on your own, the fund page shows you similar funds side by side — with their AUM and expense ratios — so you can immediately see whether a cheaper or larger competitor exists. On the QQQ page, for example, this is where you'd spot alternatives like QQQM. It turns a single-fund lookup into instant comparison shopping.
Right on the page, the built-in Compare ETFs tool lets you pit the fund against any other ticker — QQQ vs. VOO, QQQ vs. QQQM, whatever you choose — and see the differences in cost, holdings, and performance line by line. It's the fastest way to answer the question every ETF investor eventually asks: "Which of these two should I actually buy?"
#page #invesco #qqqm #real
2 months ago
There are now many signs pointing to Cincinnati Bengals receiver Ja'Marr Chase being full-go for the team's season-opener against the Tampa Bay Buccaneers. That's a good starting point for the latest Bengals player to indicate his only goals for the 2026 season are to win the Super Bowl.
Speaking during a Sept. 10 news conference at Paycor Stadium, Chase said he felt good and has taken on his normal workload in practice. Chase injured his knee during an Aug. 25 training camp practice when he collided with cornerback DJ Turner II.
The missed practices for Chase that followed the collision were precautionary, he said. Cincinnati head coach Zac Taylor said he anticipated both Chase and receiver Tee Higgins would be available for the Sept. 13 home opener, and Chase was listed in the Sept. 9-10 injury reports as a full participant in practice.
More: Dexter Lawrence may be Bengals' missing piece. Dabo Swinney, Daniel Jones, others reveal why
With health seemingly no longer threatening his ability to begin the season on time, Chase is set to begin his sixth NFL season with Super Bowl aspirations, but no personal or statistical aims he felt were worth mentioning during his Sept. 10 news conference.
#bengals #cincinnati #receiver
Speaking during a Sept. 10 news conference at Paycor Stadium, Chase said he felt good and has taken on his normal workload in practice. Chase injured his knee during an Aug. 25 training camp practice when he collided with cornerback DJ Turner II.
The missed practices for Chase that followed the collision were precautionary, he said. Cincinnati head coach Zac Taylor said he anticipated both Chase and receiver Tee Higgins would be available for the Sept. 13 home opener, and Chase was listed in the Sept. 9-10 injury reports as a full participant in practice.
More: Dexter Lawrence may be Bengals' missing piece. Dabo Swinney, Daniel Jones, others reveal why
With health seemingly no longer threatening his ability to begin the season on time, Chase is set to begin his sixth NFL season with Super Bowl aspirations, but no personal or statistical aims he felt were worth mentioning during his Sept. 10 news conference.
#bengals #cincinnati #receiver
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
